Healio

LAMA/LABA therapy reduced risk for COPD exacerbation, pneumonia hospitalization

Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...
Healio

Perioperative LAMA/LABA inhaled therapy optimal for patients with lung cancer, COPD

Please provide your email address to receive an email when new articles are posted on . Perioperative combination therapy using a long-acting muscarinic antagonist and long-acting beta agonist may be ...
Pharmabiz

GSK, Theravance announce positive results from four pivotal phase III studies for LAMA/LABA in COPD

GlaxoSmithKline plc and Theravance, Inc, a biopharmaceutical company, have announced the results of four pivotal phase III studies of investigational LAMA/LABA involving over 4,000 patients with ...
Monthly Prescribing Reference

Cardiovascular, Cerebrovascular Risk Examined for LABA/LAMA in COPD

Overall results demonstrated that for the LABA/LAMA cohort cardiovascular event frequency was 2.11% compared to 3.41% in the LABA/ICS cohort. According to a new study published in the Annals of ...
The American Journal of Managed Care

Effect of Changing COPD Triple-Therapy Inhaler Combinations on COPD Symptoms

Changing patients from an inhaled corticosteroid (ICS)/long-acting β agonist (LABA) inhaler and long-acting muscarinic agonist (LAMA) inhaler to a LAMA/LABA inhaler and a separate ICS inhaler did not ...
The New England Journal of Medicine

Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD

Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic ...
MedPage Today

LAMA Tx Didn't Up Heart Disease Risk in COPD

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- ...
Monthly Prescribing Reference

New LABA, LAMA Use May Increase Cardiovascular Disease Risk in COPD

New use of long-acting 2-agonists, antimuscarinic antagonists tied to higher CVD risk in first 30 days (HealthDay News) — For patients with chronic obstructive pulmonary disease (COPD), new initiation ...
The American Journal of Managed Care

COPD Treatment Selection

An overview of the medication classes available for the treatment of chronic obstructive pulmonary disease and recommendations for how to utilize and in whom. Transcript: Neil B. Minkoff, MD: Let’s ...
Morningstar

AeroRx Therapeutics Announces $21 Million Series A Financing to Advance Inhaled AERO-007, the First Nebulized LABA/LAMA for COPD, into Late-Stage Clinical Development

AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases, today announced the closing of a $21 ...
clinicaladvisor.com

Cardiovascular and cerebrovascular risk may decrease with LABA/LAMA in COPD

LABA/LAMA is associated with a similar or lower risk of cardiovascular and cerebrovascular adverse events compared to treatment with LABA/inhaled corticosteroid. According to a new study published in ...